RPGLIFE Stock Overview
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
RPG Life Sciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,541.95 |
| 52 Week High | ₹1,740.00 |
| 52 Week Low | ₹748.60 |
| Beta | 0.49 |
| 1 Month Change | 1.52% |
| 3 Month Change | -4.58% |
| 1 Year Change | 90.18% |
| 3 Year Change | 220.51% |
| 5 Year Change | 556.99% |
| Change since IPO | 3,334.19% |
Recent News & Updates
Recent updates
RPG Life Sciences (NSE:RPGLIFE) Is Increasing Its Dividend To ₹12.00
Jul 11
Estimating The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)
Sep 05Shareholders May Be More Conservative With RPG Life Sciences Limited's (NSE:RPGLIFE) CEO Compensation For Now
Aug 24A Look At The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)
Jun 14Are Strong Financial Prospects The Force That Is Driving The Momentum In RPG Life Sciences Limited's NSE:RPGLIFE) Stock?
Feb 09Can You Imagine How RPG Life Sciences' (NSE:RPGLIFE) Shareholders Feel About The 75% Share Price Increase?
Jan 13RPG Life Sciences (NSE:RPGLIFE) Is Growing Earnings But Are They A Good Guide?
Dec 23
Declining Stock and Solid Fundamentals: Is The Market Wrong About RPG Life Sciences Limited (NSE:RPGLIFE)?
Nov 11Estimating The Fair Value Of RPG Life Sciences Limited (NSE:RPGLIFE)
Oct 21Did Business Growth Power RPG Life Sciences' (NSE:RPGLIFE) Share Price Gain of 126%?
Sep 28What Makes RPG Life Sciences Limited (NSE:RPGLIFE) A Great Dividend Stock?
Aug 31With RPG Life Sciences Limited (NSE:RPGLIFE) It Looks Like You'll Get What You Pay For
Aug 11What You Can Learn From RPG Life Sciences Limited's (NSE:RPGLIFE) P/E
Jul 28Calculating The Intrinsic Value Of RPG Life Sciences Limited (NSE:RPGLIFE)
Jul 10Shareholder Returns
| RPGLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.4% | -0.5% | 1.4% |
| 1Y | 90.2% | 55.3% | 46.1% |
Return vs Industry: RPGLIFE exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: RPGLIFE exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| RPGLIFE volatility | |
|---|---|
| RPGLIFE Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: RPGLIFE has not had significant price volatility in the past 3 months.
Volatility Over Time: RPGLIFE's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 1,214 | Yugal Kishor Sikri | www.rpglifesciences.com |
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies. It operates in nephrology, rheumatology, oncology, gastroenterology, cardiovascular, orthopedics, respiratory, neurology, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology, pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008.
RPG Life Sciences Limited Fundamentals Summary
| RPGLIFE fundamental statistics | |
|---|---|
| Market cap | ₹25.50b |
| Earnings (TTM) | ₹847.70m |
| Revenue (TTM) | ₹5.74b |
30.1x
P/E Ratio4.4x
P/S RatioIs RPGLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPGLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹5.74b |
| Cost of Revenue | ₹1.88b |
| Gross Profit | ₹3.86b |
| Other Expenses | ₹3.01b |
| Earnings | ₹847.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 51.25 |
| Gross Margin | 67.31% |
| Net Profit Margin | 14.78% |
| Debt/Equity Ratio | 0% |
How did RPGLIFE perform over the long term?
See historical performance and comparison